Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.70 |
| ▸ | LTA4H | P09960 | 1/20 | 0.59 |
| ▸ | GSR | P00390 | 1/20 | 0.58 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.56 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | CPB2 | Q96IY4 | 5/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12173395 | 1.00 | GABRR1 (0.70) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL17974330 | 1.00 | GABRR1 (0.70) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL4017002 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL1882487 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL3680852 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL1872640 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| Hydrochloric Acid SCHEMBL2328044 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL4020912 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL10869353 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM | |
| SCHEMBL1881586 | 0.98 | GABRR1 (0.67) | GABRR1LTA4HGSRRNPEPBLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7309719-B1 | Storage stability; gabapentin and pregabalin, and neutral alpha -amino acid | WARNER LAMBERT COMPANY, LLC (US) | 2007-12-18 | — | — | US | claimed |
| EP-1077692-B1 | AMINO ACID STABILIZED GABAPENTIN AND PREGABALIN PREPARATIONS AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2004-07-28 | — | — | EP | claimed |
| WO-1999059573-A9 | STABILIZED PHARMACEUTICAL PREPARATIONS OF GAMMA-AMINOBUTYRIC ACID DERIVATIVES AND PROCESS FOR PREPARING THE SAME | WARNER LAMBERT CO (US) | 2000-05-04 | — | — | WO | claimed |
| US-6433166-B1 | — | — | None | — | — | US | disclosed |
| US-20250051577-A1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | CEPHEID (US) | 2025-02-13 | — | — | US | disclosed |
| US-12071547-B2 | Sulforhodamine phosphoramidite dyes | CEPHEID (US) | 2024-08-27 | — | — | US | disclosed |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-19 | — | — | US | disclosed |
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | AMNEAL PHARMACEUTICALS LLC (US) | 2024-03-14 | — | — | US | disclosed |
| US-20240067824-A1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | CEPHEID | 2024-02-29 | — | — | US | disclosed |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | AMNEAL PHARMACEUTICALS LLC (US) | 2023-12-26 | — | — | US | disclosed |
| EP-3790931-B1 | SULFORHODAMINE PHOSPHORAMIDITE DYES | CEPHEID (US) | 2023-09-27 | — | — | EP | disclosed |
| EP-1054864-A1 | PROCESS FOR THE PREPARATION OF EPSILON-CAPROLACTAM | DSM N.V. (NL) | 2000-11-29 | — | — | EP | disclosed |
| WO-1999042440-A1 | PROCESS FOR THE PREPARATION OF ε-CAPROLACTAM | DSM N.V. (NL) | 1999-08-26 | — | — | WO | disclosed |
| EP-0937712-A1 | Process for the preparation of E-caprolactam | DSM N.V. (NL) | 1999-08-25 | — | — | EP | disclosed |
| US-5700934-A | REACTING 5-FORMYLVALERATE ESTER WITH AMMONIA, HYDROGENATING PRODUCT IN PRESENCE OF HYDROGENATION CATALYST AND AMMONIA | DSM N.V. (NL) | 1997-12-23 | — | — | US | disclosed |
| EP-0729944-A2 | Process for the preparation of epsilon-caprolactam | DSM N.V. (NL) | 1996-09-04 | — | — | EP | disclosed |
| EP-0729943-A2 | Process for the preparation of epsilon-caprolactam and epsilon-caprolactam precursors | DSM N.V. (NL) | 1996-09-04 | — | — | EP | disclosed |
| US-5518735-A | ANTICOAGULANTS ADMINISTERED BY MOUTH | PENTAPHARM AG (CH) | 1996-05-21 | — | — | US | disclosed |
| US-5082942-A | NOVEL DERIVATIVES OF TETRAHYDRO-2,3,6,7,1H,5H,11H-(1)BENZOPYRANO(6,7,8,IJ)QUINOLIZINONE-11 USABLE AS MARKERS OF ORGANIC COMPOUNDS FOR THE DETECTION OF SAID COMPOUNDS BY CHEMILUMINESCENCE OR FLUORESCENCE | LABORATORIES EUROBIO (FR) | 1992-01-21 | — | — | US | disclosed |
| EP-0186083-A2 | N-(2-Hyxdroxyalkyl)-amino acids and their derivatives, process for their preparation and pharmaceutical compositions containing them | ASTA Pharma AG (DE) | 1986-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240082193-A1 | BACLOFEN FORMULATIONS AND METHODS OF MINIMIZING PATIENT EXPOSURE TO METABOLITE VARIATIONS | GABRB1, GABRB2, GABBR1 | GABRR1 22/4885LTA4H 1349/4885GSR 1890/4885 |
| US-11931328-B2 | Stabilized formulations of 4-amino-3-substituted butanoic acid derivatives | GABRA6, GABBR1, GABBR2 | GABRR1 29/4885LTA4H 344/4885GSR 3666/4885 |
| US-11850225-B2 | Baclofen formulations and methods of minimizing patient exposure to metabolite variations | GABRB1, GABRB2, GABBR1 | GABRR1 22/4885LTA4H 1382/4885GSR 1840/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.